Key points are not available for this paper at this time.
Design
Editorial
No takes yet. Share an insight, caveat, or question.
The withdrawal of drotrecogin alfa (activated) after the negative PROWESS-SHOCK trial underscores the risks of early drug approval based on single trials and the need for better patient selection and more efficient trial designs in critical care.
Derek C. Angus (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: